drugset / Trial / NCT00039520

Sulindac and Docetaxel in Treating Women With Metastatic or Recurrent Breast Cancer

NCT00039520

NaSingle-groupOpen-labelTreatment

Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of combining sulindac with docetaxel in treating women who have metastatic or recurrent breast cancer.

Timeline

Start
2002-01
Primary completion
2004-06
Completion
2008-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Docetaxel Small molecule Intravenous
Subject Sulindac Small molecule Oral

Indications